High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma

By  

Oncology Research and Treatment, Vol. 33, Iss. 5, 2010-04 ,pp. : 231-238

Karger

Access to resources Recommend Favorite

Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression

By  

Oncology Research and Treatment, Vol. 39, Iss. 10, 2016-09 ,pp. : 605-614

Karger

Access to resources Recommend Favorite

Down-Staging of EGFR Mutation-Positive Advanced Lung Carcinoma with Gefitinib Followed by Surgical Intervention: Follow-Up of Two Cases

By  

Oncology Research and Treatment, Vol. 32, Iss. 11, 2009-10 ,pp. : 674-677

Karger

Access to resources Recommend Favorite

A randomized phase 2 trial of erlotinib versus pemetrexed as second‐line therapy in the treatment of patients with advanced EGFR wild‐type and EGFR FISH‐positive lung adenocarcinoma

By  

CANCER, Vol. 120, Iss. 9, 2014-05 ,pp. : 1379-1386

John Wiley & Sons Inc

Access to resources Recommend Favorite

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report

By  

Case Reports in Oncology, Vol. 9, Iss. 3, 2016-10 ,pp. : 565-567

Karger

Access to resources Recommend Favorite